Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation
NCT02172508 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2014-06-24
Summary
The primary objective of the study is to investigate the effect of the combined therapy 18 μg tiotropium q.d. plus pulmonary rehabilitation versus placebo plus pulmonary rehabilitation on 6-minute walking distance (6MWD) after 7 weeks of treatment in patients with moderate to severe COPD. The secondary objective of the study includes assessments of the effects of the combined therapy 18 μg Tiotropium q.d. plus rehabilitation versus placebo plus rehabilitation on dyspnoea, constant work rate exercise endurance, daily activity and lung volumes. The third objective of the study is to investigate the correlation between the results of the 6-minute walking test (6MWT), the constant work rate exercise test (CWR) and daily activity.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
Tiotropium Inhalation Capsule
- DRUG
-
Placebo Lactose Capsule
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-01-31
- Primary Completion
- 2004-03-31
More Related Trials
-
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
NCT00152984 ·Status: COMPLETED ·Phase: PHASE4
-
Tiotropium In Exercise
NCT00525512 ·Status: COMPLETED ·Phase: PHASE4
-
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
NCT04780984 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00144326 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients
NCT00274508 ·Status: COMPLETED ·Phase: PHASE3
-
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT00240435 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
NCT01072396 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
NCT01525615 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172430 ·Status: COMPLETED ·Phase: PHASE3
-
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
NCT01483625 ·Status: COMPLETED ·Phase: PHASE4
-
Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease
NCT02177318 ·Status: COMPLETED
-
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
NCT01662986 ·Status: COMPLETED ·Phase: PHASE4
-
Tiotropium / Respimat One Year Study in COPD.
NCT00387088 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT03118765 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease
NCT00106821 ·Status: COMPLETED ·Phase: PHASE4
-
Airway Effects of Tiotropium in Patients With COPD
NCT02683668 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
NCT00737100 ·Status: COMPLETED ·Phase: PHASE2
-
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
NCT01533935 ·Status: COMPLETED ·Phase: PHASE3
-
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00274547 ·Status: COMPLETED ·Phase: PHASE3
-
Tiotropium Respimat Pharmacokinetic Study in COPD
NCT01222533 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
NCT01340209 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)
NCT00274027 ·Status: COMPLETED ·Phase: PHASE3
-
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
NCT01663987 ·Status: COMPLETED ·Phase: PHASE4
-
Tiotropium Bromide in Cystic Fibrosis
NCT01179347 ·Status: COMPLETED ·Phase: PHASE3
-
Tiotropium / Respimat One-Year Study
NCT00168831 ·Status: COMPLETED ·Phase: PHASE3